Epithalon, also written epitalon and known as the AEDG peptide, is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly and a molecular weight of about 390 Da. It was developed from epithalamin, a polypeptide extract of the pineal gland. In the laboratory it is studied mainly in cell culture for its reported effects on telomerase expression, telomere length and replicative lifespan, and it is also used as a small, polar test peptide in analytical work. This article covers its structure, proposed mechanisms, published research, applications and handling requirements, and it notes where the evidence is limited.
What is epithalon?
Epithalon is a linear tetrapeptide made of alanine, glutamic acid, aspartic acid and glycine. Its formula is C14H22N4O9, and its molecular weight is about 390.35 Da. It has no aromatic or sulfur-containing residues, and its two acidic side chains give it a net negative charge at neutral pH, so it is highly polar and water-soluble. Its sequence contains an Asp-Gly bond, which is the most reactive motif for a degradation route described in the handling section.
The peptide originates from the work of Vladimir Khavinson and colleagues at the St Petersburg Institute of Bioregulation and Gerontology. The group had studied epithalamin, a polypeptide preparation from bovine pineal tissue, and identified the Ala-Glu-Asp-Gly sequence as a short fragment that reproduced some of its reported biological effects in experimental systems. A fully synthetic tetrapeptide offered an advantage over a tissue extract: its composition could be defined, verified by HPLC and mass spectrometry, and reproduced between batches.
The compound goes by several names. “Epithalon”, “epitalon” and “epithalone” are spelling variants, and “AEDG peptide” refers to the sequence. It should not be confused with epithalamin, which is a mixture. Researchers should note that most of the early literature comes from a single research network, and that independent replication was limited until a UK laboratory published a study in 2025.
Mechanism of action
No receptor has been established for epithalon, and the proposed mechanisms are still under investigation. The best-documented observation concerns telomerase. Khavinson, Bondarev and Butyugov reported in the Bulletin of Experimental Biology and Medicine in 2003 that adding the peptide to telomerase-negative human fetal fibroblast cultures induced expression of the catalytic subunit of telomerase (hTERT), enzymatic telomerase activity and telomere elongation. Telomerase is a ribonucleoprotein that adds telomeric repeats to chromosome ends, and it is normally silent in most somatic cells.
The second proposed route is epigenetic. The Khavinson group has suggested that short peptides of this type may interact with DNA or chromatin and influence gene expression, which would explain how a tetrapeptide could change hTERT transcription. This hypothesis has not been confirmed by independent structural or biochemical work, and readers should treat it as a proposal and not an established mechanism.
The third observation concerns alternative lengthening of telomeres (ALT). In the 2025 study by Al-dulaimi and colleagues, epitalon extended telomere length in normal cells through upregulation of hTERT and telomerase activity, whereas in the breast cancer cell lines tested it appeared to act mainly through ALT activation, a telomerase-independent pathway. This suggests that the response depends on cell type.
A fourth line of work relates to the pineal gland, from which the parent extract was prepared. Animal studies from the originating group reported effects on melatonin secretion and circadian parameters, though the mechanism is unclear. For in-vitro design, two points are important: telomere length measured by qPCR is a relative estimate that differs from direct methods such as terminal restriction fragment analysis, and effects measured in cell lines cannot be assumed to apply in whole organisms.
What the research shows
Four sets of published work frame the field.
The first is the original telomerase study. Khavinson and colleagues, in the 2003 paper described above, treated telomerase-negative human fetal fibroblasts with epithalon and reported induction of hTERT expression, telomerase activity and telomere elongation. They interpreted the result as reactivation of the telomerase gene in somatic cells.
The second extended the observation to proliferative capacity. Butyugov, Bondarev, Smirnova and Khavinson reported in the same journal in 2004 that primary human fetal pulmonary fibroblasts lost their proliferative potential at passage 34 and had shortened telomeres, and that adding epithalon to ageing cells lengthened telomeres to a size comparable to early passages. The treated cells made about 10 additional passages beyond the control cells, which the authors described as overcoming the Hayflick limit. The paper is indexed on PubMed.
The third is a group of rodent studies from the same research network, which examined biomarkers of ageing, lifespan and spontaneous tumour incidence in mice and rats treated with the peptide or with epithalamin. These are described here as a research area because they were carried out by a connected group of investigators, and independent replication has not been established.
The fourth is the independent replication. Al-dulaimi, Thomas, Matta and Roberts, working at Brunel University London, reported in Biogerontology in 2025 that treating normal human mammary epithelial cells and IBR.3 fibroblasts with 1 μg/ml epitalon for three weeks produced dose-dependent telomere length extension with upregulation of hTERT mRNA and telomerase activity, while 21NT and BT474 breast cancer cells showed telomere extension through ALT activity. Telomere length was estimated by qPCR. The paper is available on PubMed. Because the study used immortalised and cancer-derived lines and a relative measurement method, its results are best read as cell-culture observations.
Research applications
Telomere biology in cell culture is the main use. Fibroblasts, epithelial cells and other lines are treated with the peptide over days to weeks, and telomerase is assessed by the TRAP assay, hTERT expression by quantitative PCR, and telomere length by qPCR, terminal restriction fragment analysis or flow-FISH. Senescence markers such as senescence-associated β-galactosidase and population doubling counts complement these readouts.
ALT research is a second area. In telomerase-negative cells, markers such as ALT-associated PML bodies and C-circles are used to determine whether a treatment engages the alternative pathway, as in the 2025 study. Chronobiology and pineal research is a third area, where animal studies of melatonin secretion and circadian parameters are carried out by licensed investigators under the Animals (Scientific Procedures) Act 1986.
Biophysics is a fourth area, covering studies of the interaction of very short peptides with DNA and chromatin, which test the proposed epigenetic mechanism. Analytical chemistry is a fifth. As a tiny, anionic, chromophore-free peptide, epithalon is a demanding test compound for HPLC and mass spectrometry, and it is useful for developing methods that resolve isomers of aspartyl peptides.
Purity, storage and handling
Verification of this peptide differs from that of most. Because it has no aromatic residues, HPLC detection must use the peptide bond absorbance at about 210 to 214 nm, which makes baseline quality and solvent purity important. The peptide is very polar and elutes early on standard reversed-phase columns, so ion-pairing conditions or hydrophilic interaction chromatography are usually needed. Mass spectrometry should confirm the intact mass, with a monoisotopic [M+H]⁺ ion expected at about m/z 391.1. The key impurity is the isoaspartyl isomer, in which the peptide backbone runs through the side-chain carboxyl of aspartate. It has exactly the same mass as the target peptide, so mass spectrometry alone cannot detect it, and chromatographic resolution is essential. Net peptide content is also important, because counter-ions and water make up a large part of a powder this small.
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing Epithalon should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and researchers asking How to buy best peptides can use those documentation requirements as a first filter when comparing vendors.
A batch-specific certificate matters because the impurity profile of a short peptide reflects the efficiency of each coupling and the conditions of cleavage, and because Asp-Gly sequences are prone to side reactions during synthesis as well as in storage. The certificate should state the batch number, HPLC conditions and chromatogram, the observed mass, the counter-ion and its content, the net peptide content and the test date. A chromatographic method that separates the isoaspartyl form should be named.
Lyophilised peptide is generally stored at -20°C, sealed and desiccated, and brought to room temperature before opening because the powder is hygroscopic. In solution, the Asp-Gly bond can cyclise to a succinimide intermediate and then open to give isoaspartate or the original aspartate, a reaction that proceeds most readily at neutral and mildly alkaline pH and is accelerated by heat. Hydrolysis of the peptide chain can also occur. Stock solutions are therefore normally prepared fresh or kept at 2-8°C for short periods in slightly acidic buffer, then divided into single-use aliquots to avoid repeated freeze-thaw cycles. Cell culture media at physiological pH and 37°C are the conditions under which isomerisation is fastest, which matters for experiments that run for days or weeks. Exact stability windows depend on buffer, pH and temperature, so they should be taken from supplier data and confirmed in-house.
Light sensitivity is minimal, because the peptide has no aromatic or sulfur-containing side chains, although storage in the dark is still good practice. Standard COSHH assessment and institutional waste procedures apply, and cell-culture work should follow the biosafety rules of the host institution.
Frequently asked questions
What is epithalon peptide made of?
Epithalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG), with the formula C14H22N4O9 and a molecular weight of about 390 Da. It was designed from epithalamin, a pineal gland extract, and is also written epitalon. It has no aromatic residues, so HPLC detection uses about 210 nm.
Is epitalon the same as epithalamin?
No. Epithalamin is a polypeptide extract of bovine pineal gland, while epithalon is the defined synthetic tetrapeptide AEDG developed from it. The synthetic form avoids the batch variability of tissue extracts and can be characterised exactly by HPLC and mass spectrometry.
What does research say about epithalon and telomerase?
Cell-culture studies reported that epithalon increased hTERT expression, telomerase activity and telomere length in human fibroblasts, first from the group that developed it and in 2025 from an independent UK laboratory. The mechanism is not fully resolved, and cell-line findings do not establish effects in whole organisms.
How should lyophilised epithalon be stored?
Lyophilised epithalon is generally stored at -20°C in a sealed, desiccated container and warmed to room temperature before opening. Reconstituted solutions are usually kept in slightly acidic buffer at 2-8°C for short periods as single-use aliquots, since the Asp-Gly bond isomerises faster at neutral pH and higher temperature.
Epithalon is supplied for in-vitro laboratory research only. It is not for human or veterinary use, and it must not be administered to people or animals.